Provided by Tiger Trade Technology Pte. Ltd.

Amgen

432.42
-4.5700-1.05%
Pre-market: 431.53-0.8900-0.21%04:01 EDT
Volume:1.74M
Turnover:752.55M
Market Cap:232.85B
PE:26.86
High:437.89
Open:437.89
Low:430.72
Close:436.99
52wk High:447.03
52wk Low:269.77
Shares:538.48M
Float Shares:536.99M
Volume Ratio:0.81
T/O Rate:0.32%
Dividend:9.80
Dividend Rate:2.27%
EPS(TTM):16.10
EPS(LYR):14.23
ROE:91.47%
ROA:8.67%
PB:19.92
PE(LYR):30.39

Loading ...

Movement Alert|Amgen Rises 3.64% in Regular Trading, Multiple Brokerages Raise Target Prices Ahead of Earnings

Market Focus
·
Jul 28

Barclays Adjusts Amgen Price Target to $360 From $350, Maintains Equalweight Rating

MT Newswires Live
·
Jul 28

Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

TIPRANKS
·
Jul 28

Amgen Inc. Stock Underperforms Friday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 25

Amgen Says Strongly Disagrees with FDA'S Proposal to Withdraw Tavneos from the U.S. Market

Reuters
·
Jul 24

Amgen : Submits Data to FDA Seeking Hearing on Tavneos Avacopan in Response to Withdrawal Proposal

THOMSON REUTERS
·
Jul 24

Amgen Inc: Strongly Disagrees with Fda's Proposal to Withdraw Tavneos from the U.S. Market

THOMSON REUTERS
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders

Simply Wall St.
·
Jul 24

Imagenebio Names Yanina Grant-huerta CFO

Reuters
·
Jul 24

Amgen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 24

Amgen and BeiGene Advance Subcutaneous Formulation of FIC Bispecific Antibody into Phase III Trial

Deep News
·
Jul 23

Sino Biopharmaceutical Stock Slips 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 23

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Amgen Reportedly to Pay $74 Million to Settle Shareholder Suit Over Delayed IRS Tax Disclosure

MT Newswires Live
·
Jul 22

Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong

Simply Wall St.
·
Jul 22

Amgen Settles Shareholder Lawsuit Claiming it Hid $10.7 Billion Tax Bill

Reuters
·
Jul 21

Sino Biopharmaceutical Stock Falls 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jul 21

Goldman Sachs Adjusts Price Target on Amgen to $427 From $425, Maintains Buy Rating

MT Newswires Live
·
Jul 20

Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong

Dow Jones
·
Jul 20